Fig. 6: Prazosin shows synergistic activity with sorafenib to inhibit cell growth, tumorigenicity, migration, and invasion in HuH7R cells.

a HuH-7 and HuH-7^R cells were exposed to varying concentrations of sorafenib either alone or in combination with 20 μM prazosin for 72 h, and viability was measured via the MTT assay. b The combined effects of prazosin (20 μM) and sorafenib (5 μM) in HuH-7^R cells were measured via the MTT assay. Combination index (CI) plots were generated using CompuSyn (CI < 1, synergistic; CI = 1, additive; CI > 1, antagonistic). Fa effect under each concentration, CI combination index. c Combined effect of prazosin and sorafenib on the tumorigenic ability of HuH-7^R cells. HuH-7^R cells were treated with prazosin and sorafenib at the indicated concentrations for 14 days, and the colony-formation assay was performed. d Synergistic effect of prazosin and sorafenib on apoptosis in resistant cancer cells. HuH-7^R cells were treated with prazosin and sorafenib at the indicated concentrations, followed by staining with Hoechst 33342, and the number of apoptotic cells was quantified. e Effect of the combination of prazosin and sorafenib on wound healing in HuH-7^R cells. The micrographs show cells that had migrated into the gap 0 and 12 h after the removal of the insert. f Synergistic effect of prazosin and sorafenib on the invasion of HuH-7^R cells examined via the Transwell assay. Cells in the central field of each insert were visualized via light microscopy and quantified. All statistical data were calculated from three independent replicates (*p < 0.05; **p < 0.01).